论文部分内容阅读
目的探讨β-catenin抑制剂FH535对人肝癌细胞系HepG2增殖的影响及可能机制。方法 HepG2细胞分为对照组和FH535用药组,使用改良3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐比色法(MTS)检测FH535对HepG2细胞增殖的影响,以Western blot法检测HepG2细胞β-catenin以及cyclin D蛋白表达水平,用实时荧光定量聚合酶链式反应(PCR)检测HepG2细胞cyclin D mRNA水平。结果 FH535能够显著抑制HepG2细胞的增殖,呈时间和剂量依赖性。与对照组相比,FH535给药组HepG2细胞内β-catenin蛋白表达无差异。FH535给药组细胞wnt/β-catenin信号通路的靶基因cyclin D的mRNA和蛋白的表达显著下降,与对照组相比差异有统计学意义(P<0.0001)。结论 FH535通过抑制cyclin D mRNA及cyclin D蛋白表达而抑制HepG2细胞增殖。
Objective To investigate the effect of FH535, a β-catenin inhibitor, on the proliferation of human hepatocellular carcinoma cell line HepG2 and its possible mechanism. Methods HepG2 cells were divided into control group and FH535 treatment group. FH535 was detected by modified 3- (4,5-dimethylthiazol-2) -2,5-diphenyltetrazolium bromide colorimetry (MTS) HepG2 cells. The expression of β-catenin and cyclin D in HepG2 cells was detected by Western blot. The level of cyclin D mRNA in HepG2 cells was detected by real-time fluorescence quantitative polymerase chain reaction (PCR). Results FH535 significantly inhibited the proliferation of HepG2 cells in a time and dose-dependent manner. Compared with the control group, there was no difference in the expression of β-catenin in HepG2 cells treated with FH535. The mRNA and protein expressions of cyclin D, a target gene of wnt / β-catenin signaling pathway, were significantly decreased in FH535-treated group compared with control group (P <0.0001). Conclusion FH535 can inhibit the proliferation of HepG2 cells by inhibiting the expression of cyclin D mRNA and cyclin D protein.